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Abstract 
Objectives: To assess the anti-erosion effects of a 0.454% stannous fluoride dentifrice versus a 
marketed dentifrice in an in situ clinical study. Methods: This was a double-blind, randomized 
and controlled, two-treatment, four-period crossover clinical study involving healthy adults.  
Each study period was 10 days.  Subjects were randomized to one of two dentifrice products 
each period: an experimental 0.454% stannous fluoride dentifrice (1100ppm fluoride) or a 
marketed 1.5% arginine-containing dentifrice (Colgate® Maximum Cavity Protection, 1450ppm 
fluoride).  Subjects wore an intra-oral appliance fitted with 2 polished human enamel samples for 
6 hours per day, swishing with the assigned dentifrice slurry twice a day in addition to sipping 
and swishing with 250ml of orange juice for 10 minutes (in increments of 25ml each minute) 
four times each day.  Contact profilometry was used to measure surface changes of tooth enamel 
over the course of the study.  Two measurements for each sample were taken at baseline and day 
10.  Results: Thirty-five subjects were randomized to treatment and 31 completed the study 
(mean age = 40 years).  At day 10, enamel loss means were 0.128 µm for the stannous fluoride 
dentifrice and 1.377 µm for the arginine-containing dentifrice, respectively (p<0.001).  This 
represents 90.7% less enamel loss for the stannous fluoride dentifrice. Both products were well 
tolerated.  Clinical Significance: The 0.454% stannous fluoride dentifrice demonstrated 
significantly greater protection to human enamel against erosive acid challenges relative to the 
marketed 1.5% arginine-containing dentifrice in this in situ clinical study. 
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Introduction 
Dental erosion is a clinical outcome resulting from a tooth demineralization process that is not 
the result of bacterial acids.1  While bacterial acids initiate a reversible, subsurface 
demineralization process that can lead to caries, dietary acids, such as those found in carbonated 
drinks, energy drinks, sports drinks, citrus fruits and many other foodstuffs can overwhelm the 
natural, pellicle-coated tooth surface and induce a surface softening of the tooth mineral.2  In 
addition to excessive exposure to acid-containing food and drink, excessive acid exposure that 
occurs as a result of gastro-esophageal reflux disease and bulimia has also been implicated as a 
contributory factor that can result in surface softening, and ultimately enamel loss of the teeth.3,4   
Once lost, this mineral cannot be restored naturally; only with significant intervention from a 
dental professional can these irreversibly damaged surfaces be repaired.   
 
While first noted on a wide scale in the United Kingdom during a national health survey of 
children,5 it is now clear that dental erosion has a global presence and is commonly found in both 
children and adults.  Although a wide range of prevalence figures have been reported in different 
surveys, an average prevalence of around 30% of a population is not uncommon.6,7  Dental 
researchers have identified using oral care products  to help prevent dental erosion.  Oral care 
products help to deliver a protective barrier onto exposed tooth surfaces that can serve as either a 
sacrificial layer or as a coating to repel erosive acid challenges.8   
 
Dentifrices formulated with stannous fluoride (SnF2) have been shown in both laboratory and in 
situ clinical studies to be highly effective against both the initiation and progression of dental 
erosion.8,9-14  In these studies, the SnF2 dentifrices tested demonstrated significantly greater 
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erosion protection benefits versus a wide range of dentifrice formulations.  This benefit was 
recognized in a recent consensus report by the European Federation  of Conservative Dentistry, 
noting that products formulated with SnF2 have been shown to be effective at slowing the 
progression of erosive tooth wear, while data for other sources of fluoride were sparse.15 One of 
the proposed mechanisms of action for SnF2 is through the deposition of an acid resistant smear 
layer onto exposed tooth surfaces via the attachment of the stannous ion to free phosphate sites at 
the enamel surface.  
 
A dentifrice formulated with a combination of sodium monofluorophosphate (SMFP), arginine 
and calcium was recently shown to be more effective in two intraoral erosion models than an 
SMFP dentifrice that did not contain arginine and calcium.16,17  In those studies, however, there 
were no comparisons made against any SnF2 dentifrices.  The aim of the current study was to 
evaluate the relative abilities of an experimental, stabilized, 0.454% SnF2 dentifrice and a 
marketed arginine-based, SMFP dentifrice to protect erosively challenged enamel specimens 
against surface enamel loss in a 10 day in situ clinical study. 
 
Methods and Materials 
Overview of in situ study  
This was a single center, double-blind, randomized, supervised-usage, 2-treatment, 4-period 
crossover study. Before study initiation, a UK NHS Research Ethics Committee approved the 
study protocol (ISRCTN registry: ISRCTN55245733 DOI 10.1186/ISRCTN55245733). Thirty-
five (35) healthy subjects consented to participate and enrolled following assessment of study 
inclusion and exclusion criteria.  During the initial screening, study participants were provided 
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with a non-treatment, marketed dentifrice containing 0.32% NaF (1450 ppm fluoride - Crest® 
Decay Protection dentifricea,) and a manual toothbrush (Oral-B®35 manual toothbrusha) for use 
at home, in place of their normal oral care products during treatment periods in the morning prior 
to their study visits and again in the evening, as well as on weekends and on days off. 
 
Test Products 
 Treatment dentifrices included in this study were: 
• Experimental Dentifricea - 0.454% SnF2 smooth texture (1100 ppm fluoride)a 
• Colgate® Maximum Cavity Protectionb – 1.1% SFMP (1450 ppm fluoride), sourced from 
the United Kingdom 
Preparation of enamel specimens 
All enamel specimens used in this study were prepared from caries-free, human, third molars that 
were donated by adult patients to a licensed tissue bank (Bristol Dental School and Hospital 
Tooth Tissue Bank, REC Ref: 11/N1/0145) following extraction.  After receipt by the tissue 
bank, donated teeth were sterilized and roots removed for further use.  
 
To prepare the enamel samples for insertion into the intraoral appliance, the disinfected tooth 
crowns obtained from the tissue bank were first sectioned into 1mm slices with a microslice.c 
The enamel slices were trimmed to fit into the appliance, as needed, using a high-speed 
handpiece and diamond bur.  Each specimen was placed, test surface down, in a 6mm x 8mm x 
2mm (width, length, thickness) mold, and the mold was filled with epoxy resin.  After curing for 
24 hours, specimens were removed from the mold and hand polished by a trained laboratory 
technician to a smooth and shiny finish using a standardized series of silicon-carbide papers, 
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silica powders and polishing techniques.  Two readings were taken on each enamel sample using 
contact profilometry in order to obtain a baseline value for each specimen.  A detailed 
description of the collection, preparation, sample tracking and analytical techniques used to 
measure the study specimens has been previously described by West et al.11  At the end of the 
study (Day 10), specimens were again measured using the calibrated contact surface profilometer 
and a difference measurement was calculated.  Fresh enamel samples were inserted into the 
appliance for each of the 4 test periods. 
 
The intraoral appliance 
Each study participant was specially fitted with an upper palatal intraoral appliance containing 
two of the prepared enamel samples.  The appliance with the fitted enamel samples was worn on 
each treatment day of the study and was held in place using wire clasps that gripped onto suitable 
posterior teeth (Figure 1).  On each of the 10 days of treatment, participants brushed their teeth at 
home, in their usual manner, with the non-treatment dentifrice.  Once they arrived at the clinical 
site, participants collected their individually prepared appliance and inserted it into their mouth.  
Study participants wore the appliances for approximately 6 hours per day on each of the 10 
treatment days of the study.  Intraoral appliances were disinfected at the start and end of each 
treatment day using Corsodyl® mouthrinse (0.2% w/v chlorhexidine gluconated). 
 
In situ product treatment 
At the beginning of the study, participants were randomly assigned to a treatment sequence that 
ordered their use of the two test dentifrices.  Twice each day (early morning and prior to lunch), 
personnel in the dispensing room at the clinical site prepared a slurry of the assigned test 
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dentifrice for each individual participant by mixing 3 grams of dentifrice and 10mL of water.  
For each treatment, participants swished for 60 seconds, under the supervision of study 
personnel, with a freshly prepared dentifrice slurry (Figure 2).  Participants removed the 
appliance over lunch, during which time they placed the appliance in a moist jar.  No food or 
drink, with the exception of water, was consumed during any period while the appliance was in 
the mouth.   
 
Participants were not aware of the identity of the dentifrices they were using during the study, 
and they were instructed not to discuss the physical characteristics of the dentifrices with other 
participants or study personnel.  As an added measure of blinding, the investigator and study 
personnel performing and recording surface profilometry measurements were not permitted in 
the product dispensing room during treatments.   
 
In situ erosive challenge 
The erosive challenge occurred with the appliance in the mouth.  Subjects were required to sip 
25mL of orange juicee over a timed minute, swish it around in their mouth to make sure it came 
into contact with the enamel specimens, and then spit it out.  This was repeated 10 times during 
each erosive challenge so that a total of 250mL of orange juice was exposed to the enamel 
samples over each 10-minute period of erosive challenge.  The erosive challenge took place a 
total of four times on each treatment day. (Figure 2) 
 
Statistical efficacy analyses 
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The primary measure of efficacy in this study was dental erosion, measured by surface 
profilometry, at Day 10.  For each subject, treatment period, and visit, the average of four 
erosion measurements was calculated using two replicate measurements from each of two 
enamel sections.  Data were transformed using the natural log function to satisfy the normality 
assumption.  A general linear mixed model was used to compare treatments with a statistical 
model that included period and treatment as fixed effects, baseline as covariate and subject as a 
random effect.  From the statistical model, estimated means on the natural log scale were back-
transformed by using the exponential function to obtain the estimated medians or 50th 
percentiles on the original scale (µm).  Statistical comparisons were two-sided at a 5% 
significance level.   
 
Results 
Thirty-five subjects signed an informed consent form and were randomized to treatment. Thirty-
one subjects completed the study.  Three subjects voluntarily withdrew from the study and one 
subject dropped out during the first study period due to a probably-related, moderate-severity 
adverse event (lip swelling). Subjects ranged in age from 21 to 59 with an average of 40.3 years 
(SD=13.5). Twenty-six (74%) of the subjects were female.  
 
At Day 10, the experimental SnF2 dentifrice demonstrated a statistically significant (p<0.001) 
lower enamel loss with the estimated median dental erosion of 0.1280 µm with 95% CI = 
(0.0935, 0.1751) for the experimental SnF2 dentifrice and 1.3772 µm with 95% CI = (1.0124, 
1.8733) for the SMFP/arginine dentifrice. The experimental SnF2 dentifrice provided 90.7% 
greater protection (based on dental enamel loss) relative to the marketed SMFP/arginine 
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dentifrice ( p<0.001). The analysis of dental erosion on the natural log scale and the estimated 
medians are summarized in Table 1. Figure 3 shows Distribution Box plots of enamel loss by 
treatment. Figure 4 shows Distribution Box Plots of natural log enamel loss by treatment.  
 
Discussion 
This study clearly confirmed the ability of the experimental, stabilized 0.454% SnF2 dentifrice to 
protect the enamel surface from dietary acid erosion.  Further, the study confirmed that this 
effect was greater than the marketed arginine-based product over the 10-day test period.  Oral 
care products are used daily by most individuals and this type of usage pattern is perfectly suited 
to delivery product therapies that can deposit onto and be retained on exposed tooth surfaces for 
extended periods of time and help protect teeth against erosive acid challenges. Many modern 
fluoride-containing products have been shown to provide some level of erosion benefit.18  
However, most of these studies have not compared the effectiveness of the tested formulations 
against those containing stannous actives.  In studies that have included stannous actives, 
stabilized SnF2 has been shown to provide a level of protection significantly greater than other 
sources of fluoride.9-14,19-21   
 
When delivered into the oral cavity, SnF2 reacts with exposed tooth surfaces to deposit a 
protective barrier layer that is likely composed of either stannous oxide or stannous 
fluorophosphate, both of which are highly acid resistant.22  Products formulated with stabilized 
SnF2 have been confirmed to deposit a long-lasting stannous-rich, acid resistant barrier layer on 
the enamel surface capable of withstanding erosive acid challenges for extended periods of time 
post treatment.9-14,19-21  
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The marketed control dentifrice used in this study contains a combination of 1450ppm F as 
SMFP, 1.5% arginine and calcium carbonate and is promoted for its ability to provide enamel 
strengthening due, in part, to the product’s claimed ability to neutralize plaque acids.  Although 
two studies sponsored by the manufacturer have demonstrated some level of benefit against 
erosive acids for a formulation that contains SMFP and 8% arginine,16,17 neither of these studies 
included a comparison of the effectiveness of the SMFP-arginine formulation versus any 
dentifrices that contained a stabilized SnF2 active.  Well-controlled in vitro erosion prevention 
studies that included a stabilized SnF2 comparator demonstrated highly significant differences, in 
favor of the SnF2 dentifrice, when compared to similar products containing SMFP and up to 8% 
arginine19,20  A recent in situ erosion prevention clinical trial provided similar results, with the 
stabilized SnF2 dentifrice included in that study performing significantly better than the 
SMFP/arginine comparator dentifrice.21 
 
This study design used an in situ model that has been well-accepted and published to assess the 
erosion protection benefits from dentifrice chemistry.9,10,21,23 Both products in the study were 
used according to the same instructions, providing controlled test conditions to ascertain the 
single-variable chemical effects of the dentifrice against erosive acid challenge.  Use of models 
designed to incorporate abrasion in addition to erosive conditions could be considered for future 
research.  
 
Conclusion 
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In the present in situ clinical study, the experimental 0.454% SnF2 dentifrice demonstrated 
significantly greater protection to human enamel against erosive acid challenges relative to the 
marketed 1.5% arginine-containing dentifrice. 
 
a. The Procter & Gamble Company, Cincinnati, OH, USA 
b. Colgate-Palmolive, New York, NY, USA 
c. Ultra Tec Ltd, Santa Ana, California, USA  
d. GlaxoSmithKline, Brentford, Middlesex, UK 
e. Sainsbury’s Supermarkets Ltd, London, UK 
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Figure 1.  Intraoral appliance with two enamel specimens  
 
 
 16 
 
 
 
Figure 2.  Daily treatment protocol 
Dentifrice slurry 
(60 sec)  → acid 
challenge (10 min)
8:30 (± 30 min)
Acid Challenge (10 
min)
10:30 (± 30 min)
Dentifrice slurry 
(60 sec) → acid 
challenge (10 min)
11:30 (± 30 min)
Lunch
Acid Challenge (10 
min)
14:30 (± 30 min)
Remove appliance 
and soak overnight 
in a moist pot
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Figure 3.  Distribution Box plots of enamel loss (m) by treatment.  
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Figure 4.  Distribution Box Plots of natural log enamel loss by treatment. 
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Table 1.  Treatment Comparison of Profilometry Levels (µm)
a
    
 
Dentifrice 
Treatment 
Original Scale in µm 
Estimated Median b 
Natural Log Scale 
Mean (SE) 
 
% Reduction vs. SMFP/ 1.5% 
arginine (p-value) c 
 
 
10 Days Post-Baseline (Subject Variance = 0.3150, Residual Variance = 0.9764 
 
Experimental  
0.454% SnF2  
0.1280 -2.0560 (0.1570) 90.7% (p<0.001) 
SMFP/ 1.5% 
arginine  
1.3772 0.3200 (0.1539)  
a Data were transformed using the natural log function to make the distribution bell-shaped before performing between-treatment 
analyses.  Treatment and Period were fixed effects, Baseline was covariate and Subjects was a random effect.  The carry-over effect was 
not statistically significant and was removed from the model. 
b Estimated medians in µm were obtained by using the exponential function on the means from the natural logarithmic scale. 
c Percent reduction was calculated using back-transformed means as 100% (SMFP-1.5% arginine – Experimental SnF2 / SMFP-1.5% 
arginine).  Two-sided p-values for testing the mean difference between treatments were provided. 
